Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neuroendocrine Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Endocrine Neoplasm
Neuroendocrine Neoplasm

Cancer Family

Neuroendocrine Neoplasm

CI-CAN-00000286NENExplore in graph →

Non-malignant700 active trials12 approved drugs34 evidence items

NCIt: C3809

Overview
Statistics
Survival
Genomics11
Variants & evidence34
Drugs21
Trials2394
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (35)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–25 of 35 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
· N Engl J Med · 2023 · PMID 37870969 · validated civic_curation pubmed
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
· N Engl J Med · 2020 · PMID 32846061 · validated civic_curation pubmed
When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?
· Ann Surg Oncol · 2009 · PMID 19472011 · validated civic_curation pubmed
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
· Cancer · 2016 · PMID 27525386 · validated civic_curation pubmed
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
· J Clin Endocrinol Metab · 2008 · PMID 18073307 · validated civic_curation pubmed
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
· J Clin Oncol · 2010 · PMID 20368568 · validated civic_curation pubmed
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
· Endocr Relat Cancer · 2015 · PMID 25376618 · validated civic_curation pubmed

Showing 1–25 of 35 publications

← Previous
1
2
Next →

Re: "A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion" by Wijewardene et al.

· Thyroid · 2023 · PMID 37376747 · validated civic_curation pubmed

Genotype-phenotype correlation of patients with multiple endocrine neoplasia type 2 in Japan.

· Jpn J Clin Oncol · 1998 · PMID 9839497 · validated civic_curation pubmed

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

· N Engl J Med · 2016 · PMID 27093365 · validated civic_curation pubmed

Clinical correlation of extensive-stage small-cell lung cancer genomics.

· Ann Oncol · 2016 · PMID 26802149 · validated civic_curation pubmed

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

· Clin Cancer Res · 2009 · PMID 19118063 · validated civic_curation pubmed

Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer.

· Lung Cancer · 2015 · PMID 25601188 · validated civic_curation pubmed

Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.

· Cancer Discov · 2014 · PMID 24934408 · validated civic_curation pubmed

Selective RET kinase inhibition for patients with RET-altered cancers.

· Ann Oncol · 2018 · PMID 29912274 · validated civic_curation pubmed

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.

· J Thorac Oncol · 2020 · PMID 31988000 · validated civic_curation pubmed

Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma.

· N Engl J Med · 2015 · PMID 26466009 · validated civic_curation pubmed

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.

· Cancer Discov · 2016 · PMID 27048246 · validated civic_curation pubmed

Germline mutations in the vhl gene in patients presenting with phaeochromocytomas.

· Int J Cancer · 1998 · PMID 9663592 · validated civic_curation pubmed

Paraganglioma in a 13-year-old girl: a novel SDHB gene mutation in the family?

· Cancer Genet Cytogenet · 2010 · PMID 20193854 · validated civic_curation pubmed

RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases.

· Oncotarget · 2018 · PMID 29515777 · validated civic_curation pubmed

Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor.

· Cold Spring Harb Mol Case Stud · 2019 · PMID 31160355 · validated civic_curation pubmed

CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.

· Cancer Res · 2017 · PMID 28490518 · validated civic_curation pubmed

Anti-tumor activity of motesanib in a medullary thyroid cancer model.

· J Endocrinol Invest · 2012 · PMID 21422803 · validated civic_curation pubmed

AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.

· PLoS One · 2012 · PMID 23056499 · validated civic_curation pubmed